Clovis Oncology Competitors

Clovis Oncology (NASDAQ:CLVS) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Analyst Ratings

This is a summary of current ratings for Clovis Oncology and Amgen, as reported by MarketBeat.com.

Clovis Oncology presently has a consensus price target of $9.50, suggesting a potential upside of 52.49%. Amgen has a consensus price target of $259.4091, suggesting a potential upside of 4.20%. Given Clovis Oncology's higher possible upside, research analysts clearly believe Clovis Oncology is more favorable than Amgen.

Profitability

This table compares Clovis Oncology and Amgen's net margins, return on equity and return on assets.

Institutional & Insider Ownership

57.8% of Clovis Oncology shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 6.6% of Clovis Oncology shares are owned by company insiders. Comparatively, 0.4% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Clovis Oncology and Amgen's gross revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Clovis Oncology. Clovis Oncology is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Clovis Oncology has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Summary

Amgen beats Clovis Oncology on 11 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Clovis Oncology (NASDAQ:CLVS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Volatility and Risk

Gilead Sciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Clovis Oncology has a beta of 2.1, meaning that its stock price is 110% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Gilead Sciences and Clovis Oncology, as reported by MarketBeat.

Gilead Sciences currently has a consensus price target of $97.2308, suggesting a potential upside of 49.33%. Clovis Oncology has a consensus price target of $9.50, suggesting a potential upside of 52.49%. Given Clovis Oncology's higher possible upside, analysts plainly believe Clovis Oncology is more favorable than Gilead Sciences.

Institutional and Insider Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. Comparatively, 57.8% of Clovis Oncology shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by company insiders. Comparatively, 6.6% of Clovis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Gilead Sciences and Clovis Oncology's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Gilead Sciences and Clovis Oncology's gross revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher revenue and earnings than Clovis Oncology. Clovis Oncology is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Clovis Oncology on 10 of the 14 factors compared between the two stocks.

Clovis Oncology (NASDAQ:CLVS) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Earnings & Valuation

This table compares Clovis Oncology and Vertex Pharmaceuticals' revenue, earnings per share and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Clovis Oncology. Clovis Oncology is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Clovis Oncology and Vertex Pharmaceuticals, as reported by MarketBeat.

Clovis Oncology presently has a consensus target price of $9.50, suggesting a potential upside of 52.49%. Vertex Pharmaceuticals has a consensus target price of $293.1250, suggesting a potential upside of 37.39%. Given Clovis Oncology's higher probable upside, equities analysts clearly believe Clovis Oncology is more favorable than Vertex Pharmaceuticals.

Volatility and Risk

Clovis Oncology has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Profitability

This table compares Clovis Oncology and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

57.8% of Clovis Oncology shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 6.6% of Clovis Oncology shares are held by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Vertex Pharmaceuticals beats Clovis Oncology on 12 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Clovis Oncology (NASDAQ:CLVS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Profitability

This table compares Regeneron Pharmaceuticals and Clovis Oncology's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Regeneron Pharmaceuticals and Clovis Oncology's top-line revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Clovis Oncology. Clovis Oncology is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 57.8% of Clovis Oncology shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 6.6% of Clovis Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Regeneron Pharmaceuticals and Clovis Oncology, as provided by MarketBeat.com.

Regeneron Pharmaceuticals presently has a consensus price target of $637.2083, suggesting a potential upside of 34.10%. Clovis Oncology has a consensus price target of $9.50, suggesting a potential upside of 52.49%. Given Clovis Oncology's higher probable upside, analysts plainly believe Clovis Oncology is more favorable than Regeneron Pharmaceuticals.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Clovis Oncology has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500.

Summary

Regeneron Pharmaceuticals beats Clovis Oncology on 13 of the 15 factors compared between the two stocks.

Clovis Oncology (NASDAQ:CLVS) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk.

Volatility and Risk

Clovis Oncology has a beta of 2.1, meaning that its stock price is 110% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Clovis Oncology and Biogen, as reported by MarketBeat.

Clovis Oncology currently has a consensus target price of $9.50, suggesting a potential upside of 52.49%. Biogen has a consensus target price of $303.5517, suggesting a potential upside of 13.19%. Given Clovis Oncology's higher probable upside, equities analysts plainly believe Clovis Oncology is more favorable than Biogen.

Insider & Institutional Ownership

57.8% of Clovis Oncology shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 6.6% of Clovis Oncology shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Clovis Oncology and Biogen's top-line revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than Clovis Oncology. Clovis Oncology is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Clovis Oncology and Biogen's net margins, return on equity and return on assets.

Summary

Biogen beats Clovis Oncology on 10 of the 14 factors compared between the two stocks.

Clovis Oncology (NASDAQ:CLVS) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Clovis Oncology and Alexion Pharmaceuticals, as provided by MarketBeat.

Clovis Oncology presently has a consensus price target of $9.50, indicating a potential upside of 52.49%. Alexion Pharmaceuticals has a consensus price target of $153.8636, indicating a potential downside of 0.74%. Given Clovis Oncology's higher probable upside, equities analysts clearly believe Clovis Oncology is more favorable than Alexion Pharmaceuticals.

Earnings & Valuation

This table compares Clovis Oncology and Alexion Pharmaceuticals' gross revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Clovis Oncology. Clovis Oncology is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

57.8% of Clovis Oncology shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 6.6% of Clovis Oncology shares are held by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Clovis Oncology and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Risk and Volatility

Clovis Oncology has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Clovis Oncology on 12 of the 15 factors compared between the two stocks.